Cannabivarin (CBV) and tetrahydrocannabivarin (THCV) both produced dose-dependent pain relief in a worm model through vanilloid and cannabinoid-like receptor pathways.
Pain researchers, pharmacologists interested in minor cannabinoids, and neuroscience enthusiasts.
Two non-psychoactive cannabinoids with analgesic effects via dual pathways
What the researchers found
Both CBV and THCV produced dose-dependent antinociceptive effects in C. elegans thermotaxis assays. Experiments with mutant worm strains showed the pain-relieving effects were mediated through vanilloid receptor homologs (OCR-2, OSM-9) and cannabinoid receptor homologs (NPR-19, NPR-32). Proteomics identified the biological pathways involved.
Why it matters
CBV and THCV are non-psychoactive cannabinoids that have received far less research attention than CBD and THC. Demonstrating their analgesic mechanisms through conserved receptor pathways supports further investigation in mammalian pain models.
The numbers in context
Both compounds showed dose-dependent pain relief. Effects mediated through OCR-2 and OSM-9 (vanilloid homologs) and NPR-19 and NPR-32 (cannabinoid homologs). Proteomics identified associated biological pathways.
How the study worked
Thermotaxis assays in wild-type and mutant C. elegans strains (deficient in vanilloid and cannabinoid receptor homologs) to establish dose-response relationships and identify molecular targets. Mass spectrometry proteomics combined with network biology analysis.
What this study cannot tell us
C. elegans is a nematode worm, and while receptor homologs are conserved, translating findings to mammalian or human pain is highly uncertain. The study establishes mechanism but cannot predict therapeutic efficacy in humans.
How to read the evidence
Basic science study in a nematode model. Establishes mechanism but very far from human therapeutic application.
When this study was published
2026 study.
The bigger picture
The cannabis plant contains over 100 cannabinoids, most of which are poorly studied. Finding that minor cannabinoids like CBV and THCV have pain-relieving properties through identified receptor pathways expands the potential pharmacological toolkit beyond CBD and THC.
Questions still open
- Do CBV and THCV show similar analgesic effects in mammalian pain models? Could these compounds be developed as non-psychoactive alternatives to THC for pain management?
Common questions
What are CBV and THCV?
Could these become pain medications?
Read the original research
Cannabivarin and tetrahydrocannabivarin modulate nociception via vanilloid channels and cannabinoid-like receptors in Caenorhabditis elegans.
Canadian journal of physiology and pharmacology, 104, 1-13
Citation
Rahmani, Nasim; Castaño, Jesus D; Beaudry, Francis. (2026). Cannabivarin and tetrahydrocannabivarin modulate nociception via vanilloid channels and cannabinoid-like receptors in Caenorhabditis elegans.. Canadian journal of physiology and pharmacology, 104, 1-13. https://doi.org/10.1139/cjpp-2025-0243
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk